Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Asia Pacific Pharmaceutical CDMO Market, 2019-2030, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical CDMO Market 26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical CDMO Market 31
Figure 9. Investment Opportunity Analysis 35
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical CDMO Market 38
Figure 11. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue 42
Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 43
Figure 13. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn 44
Figure 14. Asia Pacific Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn 45
Figure 15. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue 46
Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%) 47
Figure 17. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn 48
Figure 18. Asia Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 49
Figure 19. Asia Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 50
Figure 20. Asia Pacific Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn 52
Figure 21. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn 53
Figure 22. Asia Pacific Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 55
Figure 23. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn 56
Figure 24. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn 57
Figure 25. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn 58
Figure 26. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn 59
Figure 27. Asia Pacific Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn 60
Figure 28. Asia Pacific Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn 61
Figure 29. Asia Pacific Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn 62
Figure 30. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 64
Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 64
Figure 32. Asia Pacific Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn 65
Figure 33. Asia Pacific Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn 66
Figure 34. Asia Pacific Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn 67
Figure 35. Asia Pacific Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn 68
Figure 36. Asia Pacific Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn 69
Figure 37. Asia Pacific Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn 70
Figure 38. Asia Pacific Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn 71
Figure 39. Asia Pacific Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn 72
Figure 40. Breakdown of Asia Pacific Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue 73
Figure 41. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%) 74
Figure 42. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 75
Figure 43. Asia Pacific Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn 76
Figure 44. Asia Pacific Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn 77
Figure 45. Breakdown of APAC Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue 79
Figure 46. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 80
Figure 47. Pharmaceutical CDMO Market in Japan, 2019-2030, $ bn 82
Figure 48. Pharmaceutical CDMO Market in China, 2019-2030, $ bn 84
Figure 49. Pharmaceutical CDMO Market in Australia, 2019-2030, $ bn 86
Figure 50. Pharmaceutical CDMO Market in India, 2019-2030, $ bn 88
Figure 51. Pharmaceutical CDMO Market in South Korea, 2019-2030, $ bn 90
Figure 52. Pharmaceutical CDMO Market in Rest of APAC, 2019-2030, $ bn 92
Figure 53. Growth Stage of Asia Pacific Pharmaceutical CDMO Industry over the Forecast Period 94
Asia Pacific pharmaceutical CDMO market will grow by 8.3% annually with a total addressable market cap of $725.2 billion over 2020-2030 owing to the rising demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures. Highlighted with 44 tables and 53 figures, this 136-page report “Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on a comprehensive research of the entire Asia Pacific pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country. Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Pharmaceutical Contract Manufacturing Organization (CMO) • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing) • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs) • Secondary Packaging Pharmaceutical Contract Research Organization (CRO) • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Company Profiles of CMO: Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH 8.3.2 Company Profiles of CRO: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK Asia Pacific Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More